Trial Profile
A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Imaradenant (Primary) ; Oleclumab (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 22 Jan 2024 Planned End Date changed from 25 Sep 2024 to 15 Jan 2025.
- 30 Jun 2023 Planned End Date changed from 3 Jan 2024 to 25 Sep 2024.
- 13 Feb 2023 Planned End Date changed from 1 Dec 2022 to 3 Jan 2024.